Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Acquisition Details:
Roche has acquired Poseida Therapeutics, a CAR-T cell therapy developer, for $1 billion upfront4.
Strategic Move:
This acquisition is part of Roche's strategy to strengthen its presence in the cell therapy market, particularly in CAR-T therapies for blood cancers23.
Previous Collaboration:
Roche and Poseida had a collaboration agreement since 2021 to develop allogeneic CAR-T cell therapies, with Poseida receiving $110 million upfront and potential milestone payments2.
Market Impact:
This acquisition underscores Roche's commitment to advancing cell therapy research and its competitive position in the biopharmaceutical industry23.
Recent Developments:
Roche has been actively investing in gene therapy and cell therapy technologies, including a recent $1 billion deal with Dyno Therapeutics for neurological diseases13.
Sources:
1. https://www.biospace.com/business/roche-inks-potential-1b-gene-therapy-deal-with-dyno-eyes-neurological-diseases
2. https://www.biopharmadive.com/news/roche-genentech-adaptimmune-cancer-cell-therapy-deal-terminated/713076/